Screener
Allogene Therapeutics ALLO Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -42.4%+12.7pp | -52.3%+7.3pp | -53.4%+1.7pp | -54.4%-0.2pp | -55.1%-5.9pp | |
| Return on invested capital | -43.2%+20.6pp | -51.3%+7.3pp | -56.5%+1.6pp | -53.7%+0.8pp | -63.8%-5.0pp | |
| Liquidity | ||||||
| Current ratio | 10.7×+1.8× | 9.6×-0.1× | 7.9×-0.6× | 8.2×-1.2× | 8.9×-3.3× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×-0.1× | 0.3×+0.1× | 0.3×+0.1× | 0.3×+0.1× | 0.3×+0.1× | |
| Per Share | ||||||
| Book value per share | $1.33-15.7% | $1.16-35.1% | $1.33-38.8% | $1.42-35.9% | $1.57-41.9% | |
| Valuation | ||||||
| Market capitalization | $532.06M+85.9% | $594.82M+87.5% | $307.88M-31.1% | $275.13M-53.0% | $273.41M-43.8% | |
| Price / book | 1.2×+0.3× | 2.1×+1.3× | 1.1×0.0× | 0.9×-0.4× | 0.8×-0.2× |
FAQ
- Where do Allogene Therapeutics's ratios come from?
- Every ratio is computed from Allogene Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
